| P2093 | author name string | Zeng Wang | |
| | Zhong Shi | |
| | Haijun Zhong | |
| | Wangxia Lv | |
| | Meiqin Yuan | |
| | Yunshan Yang | |
| | Fangxiao Lu | |
| | Yazhen Zhao | |
| P2860 | cites work | Chemotherapy for advanced gastric cancer | Q24236634 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 |
| | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine | Q28255790 |
| | Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 |
| | S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 |
| | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial | Q34634936 |
| | Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis | Q34655369 |
| | Status of treatment for advanced gastric carcinoma | Q35095365 |
| | Advanced gastric cancer--slow but steady progress | Q37696790 |
| | Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q42608504 |
| | Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. | Q43205169 |
| | Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study | Q43264239 |
| | A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis | Q44607992 |
| | Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. | Q53384216 |
| | Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. | Q53667890 |
| | [Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment] | Q73525427 |
| | Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer | Q87412385 |
| P433 | issue | 4 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 606-612 | |
| P577 | publication date | 2017-02-10 | |
| P1433 | published in | Molecular and Clinical Oncology | Q27725125 |
| P1476 | title | The significance of multi-line chemotherapy for advanced gastric cancer: A retrospective analysis | |
| P478 | volume | 6 | |